Cite
ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50.
MLA
Gerlach, Elliot S., et al. “ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus Neoformans Clinical Isolates With High and Low Fluconazole IC50.” Frontiers in Cellular & Infection Microbiology, vol. 11, June 2021, pp. 1–6. EBSCOhost, https://doi.org/10.3389/fcimb.2021.695240.
APA
Gerlach, E. S., Altamirano, S., Yoder, J. M., Luggya, T. S., Akampurira, A., Meya, D. B., Boulware, D. R., Rhein, J., & Nielsen, K. (2021). ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50. Frontiers in Cellular & Infection Microbiology, 11, 1–6. https://doi.org/10.3389/fcimb.2021.695240
Chicago
Gerlach, Elliot S., Sophie Altamirano, J. Marina Yoder, Tony S. Luggya, Andrew Akampurira, David B. Meya, David R. Boulware, Joshua Rhein, and Kirsten Nielsen. 2021. “ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus Neoformans Clinical Isolates With High and Low Fluconazole IC50.” Frontiers in Cellular & Infection Microbiology 11 (June): 1–6. doi:10.3389/fcimb.2021.695240.